Gestational diabetes mellitus: the role of IGF-1 and leptin in cord blood

What Was Tested

The paper reports a study of IGF-1 LR3, published as a observational study.

Newborns' large for gestational age status (LGA) may result from (1) parental factors, mainly high maternal height, (2) bad control of hyperglycemia in diabetic mothers, (3) undetected gestational diabetes mellitus (GDM).

Maternal hyperglycemia might lead to specific profiles of biochemical markers in cord blood, which allow detection of this metabolic dysregulation in pregnancy even after birth of an LGA infant.

Who Took Part

PubMed indexes the participants as adults, women only.

Prospective observational study over a 5-months period. 127 mother-infant-dyads were enrolled: 63 with GDM, 17 with fetal macrosomia (FM), 47 in the control group (C).

Measurement of IGF-1, insulin, leptin, fructosamine and retinol-binding protein 4 from cord blood by ELISA.

How the Study Was Run

A time span of 5 months appears in the methods.

The GDM group comprised 6 LGA newborns (GDM-LGA) vs. 57 without LGA (GDM-non-LGA).

Collection of data on maternal medical history, oral glucose tolerance testing and fetal ultrasound.

Anthropometric and metabolic data collected from mother and infant dyads.

What Was Measured

PubMed files the paper under topics including Diabetes, Gestational, Leptin, Insulin-Like Growth Factor I, Fetal Blood, Fetal Macrosomia, Biomarkers and Insulin.

Author keywords: IGF-1, LGA newborns and gestational diabetes mellitus.

What This Means in Plain Language

This is a observational study of IGF-1 LR3 over 5 months.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Journal of perinatal medicine), a journal based in Germany.

More context: the IGF-1 LR3 compound page, all human trials.